Lilly launches pill, FDA asks follow‑up

Eli Lilly has started shipping its new weight-loss pill Foundayo across the United States, even as the Food and Drug Administration orders more liver-safety studies after approval. (investor.lilly.com) (accessdata.fda.gov) Foundayo is Lilly’s brand name for orforglipron, a once-daily glucagon-like peptide-1 pill cleared on April 1, 2026 for adults with obesity, or overweight with at least one weight-related medical problem. The drug is meant to be used with a reduced-calorie diet and more physical activity. (investor.lilly.com) (accessdata.fda.gov) Glucagon-like peptide-1 drugs copy a gut hormone that helps people feel fuller and eat less. Lilly says Foundayo can be taken once a day with or without food, and without water restrictions, which sets it apart from earlier pills in the category. (investor.lilly.com) (pi.lilly.com) Lilly said on April 9 that patients can get the pill through LillyDirect, telehealth providers and retail pharmacies nationwide. The company set self-pay pricing starting at $149 a month at the lowest dose, while eligible commercially insured patients with coverage may pay as little as $25 a month. (investor.lilly.com) (hlth.com) The rollout widens a market that has been dominated by injectable obesity drugs from Lilly and Novo Nordisk. Lilly is also using a direct-to-patient model it began building in January 2024 with LillyDirect, a platform that links patients to prescribers, pharmacy fulfillment and home delivery. (hlth.com 1) (hlth.com 2) In Lilly’s ATTAIN-1 study, patients who stayed on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds on placebo. Across all participants, including those who did not finish the trial, average weight loss was 25 pounds, or 11.1%, versus 5.3 pounds on placebo. (investor.lilly.com 1) (investor.lilly.com 2) The label still carries the class warnings common to glucagon-like peptide-1 drugs, including a boxed warning about thyroid C-cell tumors seen in rodents. It also warns about pancreatitis, severe gastrointestinal reactions, kidney injury tied to dehydration and low blood sugar when used with insulin or certain diabetes drugs. (pi.lilly.com) The Food and Drug Administration approval letter says Lilly must run post-marketing studies under federal law after approval. The public letter confirms the requirement but does not spell out the liver-injury protocol in the excerpt available through the agency’s Drugs@FDA posting. (accessdata.fda.gov) That leaves Lilly in a familiar position for obesity drugs: expand access fast, then keep building the safety record in wider real-world use. For patients, the next step is simpler than the regulatory file — a prescription, a pharmacy channel and a close watch on how the drug performs outside trials. (investor.lilly.com) (accessdata.fda.gov)